Teleflex Announces Latest Peer-Reviewed Study Demonstrates a Significant Reduction in CLABSI Risk with Arrowg+ard™ Technology

Peer-reviewed publication in the American Journal of Infection Control demonstrates the use of CVCs protected with Arrowg+ard™ Technology are associated with a statistically significant and clinically meaningful reduction in the hazard of CLABSI compared with plain CVCs1.

WAYNE, Pa., September 29, 2026--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters (CVCs) protected with Arrowg+ard™ Technology were associated with a statistically significant 70% lower hazard of central line-associated bloodstream infections (CLABSIs) compared with plain, non-impregnated catheters during a 30-day period.1

CLABSI remains among the most serious healthcare-associated infections, increasing patient risk, length of stay and morbidity, and increased healthcare costs.2 In this prospective multinational study of 1,750 critically ill patients across six hospitals in four countries, patients receiving CVCs protected with Arrowg+ard™ Technology experienced a 70% lower risk of CLABSI during the 30-day period than patients receiving plain CVCs (HR 0.297; 95% CI 0.134-0.658; p=0.003).1

"At Teleflex, we are committed to investing in and generating clinical evidence necessary to support informed healthcare decision-making," said Jake Newman, President and General Manager, Global Vascular and Emergency Medicine, Teleflex. "These findings strengthen the clinical evidence supporting Arrowg+ard™ Technology and reinforce our commitment to developing innovations that help clinicians and improve patient outcomes."

"Preventing healthcare-associated infections remains a critical priority for clinicians and healthcare systems worldwide," said Dr. Amy Bardin, Vice President, Clinical and Medical Affairs, Teleflex. "Clinicians rely on high-quality clinical evidence to inform infection prevention strategies. This multinational study adds important clinical evidence supporting Arrowg+ard™ Technology and demonstrates a statistically significant association with reduced CLABSI hazard among critically ill patients".

The recently published study builds upon Teleflex's previously announced 2025 multinational prospective cohort study, which demonstrated a 70.5% reduction in overall CLABSI incidence among patients receiving Arrowg+ard Blue™ or Arrowg+ard Blue Plus™ CVCs compared with plain CVCs.2 While the 2025 publication focused on overall CLABSI incidence, the latest analysis evaluated time-to-infection, demonstrating that patients receiving catheters protected with Arrowg+ard™ Technology remained significantly less likely to develop CLABSI throughout the 30-day catheterization period. Together, these complementary studies provide evidence of both reduced overall infection burden and reduction in infection risk over time.